QUEST Fax Form
A prior authorization request form used by HMSA/CVS Caremark for specialty prescription benefit review of rituximab products (Rituxan, Riabni, Ruxience, Truxima) across multiple indications; collects patient/provider data, indication-specific screening questions, and re-authorization evidence requirements to facilitate coverage decisions.
No material clinical/coverage changes reported.
Policy Overview
This form is the QUEST prior authorization fax used by HMSA/CVS Caremark to request coverage review for rituximab products. It lists the requested products as Rituxan, Riabni, Ruxience, and Truxima and collects patient and prescriber administrative data, diagnosis (ICD-10), indication-specific clinical screening questions, and documentation to support initial or re‑authorization decisions. The form is intended to support multiple autoimmune, hematologic, neurologic, renal, and oncologic indications by directing the requester to the appropriate indication pathway on the questionnaire.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.